Sequencing Strategies in Metastatic Pancreatic Cancer

John L. Marshall, MD; George P. Kim, MD; Eileen M. O’Reilly, MD; Tanios S. Bekaii-Saab, MD; and Kabir Mody, MD, evaluate sequencing strategies beyond nab-paclitaxel plus gemcitabine, and review data from the NAPOLI-1 trial introducing nanoliposomal irinotecan in combination with 5-FU in second-line settings.